NHC (NHC) director LaRoche awarded 7,500-share stock option grant at $171.42
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
National Healthcare Corp director Richard F. LaRoche Jr reported updated holdings and a new stock option grant. He now directly holds 213,260 shares of common stock in his or his wife's name. On May 7, 2026, he received an option to purchase 7,500 shares of common stock at an exercise price of $171.42 per share.
The new 2026 option grant, issued under the 2020 Omnibus Equity Incentive Plan, becomes exercisable on May 7, 2027 and expires on May 6, 2031. LaRoche also continues to hold prior option awards from 2022, 2023, 2024 and 2025, each covering 7,500 underlying shares at exercise prices ranging from $55.75 to $96.03 per share.
Positive
- None.
Negative
- None.
Insights
Filing shows a routine equity award and updated option profile.
Director Richard F. LaRoche Jr received an option grant for 7,500 shares at an exercise price of $171.42, exercisable starting on May 7, 2027 and expiring on May 6, 2031. This is compensation-related, not an open-market trade.
He continues to hold multiple prior option grants, each for 7,500 underlying shares with exercise prices between $55.75 and $96.03, plus 213,260 directly held common shares. Overall, the activity reflects ongoing long-term equity alignment rather than a change in his economic exposure.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
LAROCHE RICHARD F JR
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock [2026 Grant] | 7,500 | $0.00 | -- |
| holding | Option to Purchase Common Stock [2022 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2023 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2024 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2025 Grant] | -- | -- | -- |
| holding | Common Stock - Held in my name or my wife's name | -- | -- | -- |
Holdings After Transaction:
Option to Purchase Common Stock [2026 Grant] — 7,500 shares (Direct, null);
Option to Purchase Common Stock [2022 Grant] — 7,500 shares (Direct, null);
Option to Purchase Common Stock [2023 Grant] — 7,500 shares (Direct, null);
Option to Purchase Common Stock [2024 Grant] — 7,500 shares (Direct, null);
Option to Purchase Common Stock [2025 Grant] — 7,500 shares (Direct, null);
Common Stock - Held in my name or my wife's name — 213,260 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
New option grant size: 7,500 shares
New option exercise price: $171.42/share
Common shares held: 213,260 shares
+4 more
7 metrics
New option grant size
7,500 shares
2026 stock option grant underlying common shares
New option exercise price
$171.42/share
Exercise price for 2026 grant, exercisable from May 7, 2027
Common shares held
213,260 shares
Directly held common stock after reported transactions
2025 option grant
7,500 shares at $94.66
Underlying shares and exercise price, expires May 7, 2030
2024 option grant
7,500 shares at $96.03
Underlying shares and exercise price, expires May 8, 2029
2023 option grant
7,500 shares at $55.75
Underlying shares and exercise price, expires May 3, 2028
2022 option grant
7,500 shares at $69.19
Underlying shares and exercise price, expires May 4, 2027
Key Terms
Option to Purchase Common Stock, 2020 Omnibus Equity Incentive Plan, Rule 16b-3(d), Section 16(b), +1 more
5 terms
Option to Purchase Common Stock financial
"security_title": "Option to Purchase Common Stock [2026 Grant]""
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan"
Rule 16b-3(d) regulatory
"exempt from Section 16(b) pursuant to Rule 16b-3(d)"
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did NHC director Richard F. LaRoche Jr report?
Richard F. LaRoche Jr reported receiving a stock option grant for 7,500 shares of National Healthcare Corp common stock. The options were granted at a $171.42 exercise price and are part of his equity compensation, rather than an open-market purchase or sale.
What are the key terms of the 2026 stock option grant reported by NHC?
The 2026 grant is an option to purchase 7,500 shares of National Healthcare Corp common stock at a $171.42 exercise price. It becomes exercisable on May 7, 2027 and expires on May 6, 2031, providing long-dated, performance-tied compensation exposure.
What other stock options does Richard F. LaRoche Jr hold in NHC?
Beyond the 2026 grant, LaRoche holds four prior option awards from 2022–2025, each covering 7,500 underlying shares. Exercise prices range from $55.75 to $96.03 per share, with expirations between 2027 and 2030, indicating a layered schedule of potential future exercises.
Under which plan was the new NHC option grant to LaRoche issued?
The new stock option grant to LaRoche was issued under National Healthcare Corp’s 2020 Omnibus Equity Incentive Plan. The filing notes the grant and any exercise are exempt from Section 16(b) short-swing profit rules pursuant to Rule 16b-3(d), confirming its compensation nature.